Physician profile
Perry Pratt
NPI 1952712721
$6,091.07
in general payments reported to CMS, 2019-2025
29 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2021: $681 · 2022: $1,968 · 2023: $1,669 · 2024: $1,312 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,289 · Education: $22.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,288.59 |
| Education | $22.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,359.80 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $990.39 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $763.00 | 2019-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $374.63 | 2022-2024 | Ibsrela |
| Celgene Corporation | $313.55 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $291.58 | 2021-2024 | Sucraid, Sucraid |
| Pfizer INC. | $252.88 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $196.23 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $166.58 | 2021-2024 | Ocaliva |
| Janssen Biotech, INC. | $142.24 | 2022-2024 | Stelara, Simponi Aria, Simponi |
| Ironwood Pharmaceuticals, INC | $138.79 | 2022-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $123.47 | 2021-2023 | |
| Medtronic, INC. | $104.39 | 2022 | |
| Gilead Sciences, INC. | $95.51 | 2021-2024 | |
| Braintree Laboratories, INC. | $93.54 | 2022-2024 | Sutab |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $87.12 | 2023 | |
| Pentax of America, INC. | $82.49 | 2022 | |
| Amgen INC. | $78.63 | 2022 | |
| Ethicon US, LLC | $72.62 | 2025 | Linx Reflux Management System |
| Phathom Pharmaceuticals, INC. | $57.89 | 2023-2024 | Voquezna |
| Redhill Biopharma INC. | $57.69 | 2021-2022 | |
| Madrigal Pharmaceuticals | $50.96 | 2024 | Resmetirom |
| Exact Sciences Corporation | $40.88 | 2023 | Cologuard Collection Kit |
| Mallinckrodt Hospital Products INC. | $32.62 | 2023 | Terlivaz |
| Ferring Pharmaceuticals INC. | $31.25 | 2022 | |
| Fresenius Kabi USA, LLC | $30.32 | 2023 | Idacio |
| Lucid Diagnostics INC. | $22.69 | 2023 | |
| Celltrion USA INC. | $22.66 | 2024 | Zymfentra |
| E.R. Squibb & Sons, L.L.C. | $16.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Pratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.